PRKD2

Across TCGA pan-cancer cohorts, PRKD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRKD2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PRKD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKD2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, PRAD, and SKCM are the cancer types where PRKD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.187	0.540	.003	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.869	0.611	.014	2	view →
COAD	DFS	Median	All	0.207	0.570	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRKD2–ESCA (DFS)

Open the ESCA breakdown →